New 'Smart' cancer drug seeks to target tumors without harsh side effects
NCT ID NCT05947474
Summary
This is an early-stage study to test the safety and find the right dose of a new investigational drug called ORB-011 for people with advanced solid tumors. The drug is designed to activate a powerful immune signal only inside specific immune cells near the tumor, aiming to fight cancer while avoiding body-wide side effects. The study will enroll about 55 adults with various advanced cancers who have already tried all standard treatments available to them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
MD Anderson Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.